SecBot SecBot
Biotech Drug Report Generated Nov 6, 2026

cliramitug

RPRX·Royalty Pharma plc
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 3
Time to market
The Phase 3 primary completion date is estimated around December 2027, with study completion around April 2028. If results are positive, an FDA submission would follow, putting a potential approval decision no earlier than late 2028 or 2029.
Why 3/10
No hard, dated catalyst for cliramitug is scheduled within the next ~12 months. The Phase 3 DepleTTR-CM trial has a primary completion date estimated around December 2027, more than 12 months away. Additionally, Royalty Pharma holds only a 3-4% royalty interest in cliramitug, not the drug itself, making it a small component of a diversified royalty portfolio. The company's nearer-term binary catalyst is the November 27, 2026 PDUFA for neladalkib, a different drug entirely.
Actionable Insight NEUTRAL

Cliramitug has no near-term catalyst for RPRX. The next meaningful event is the Phase 3 DepleTTR-CM topline readout, estimated around December 2027. RPRX investors should focus on nearer-term drivers: the November 27, 2026 PDUFA for neladalkib (a separate royalty asset) and the company's Q4 earnings. Cliramitug is a long-term call option within RPRX's portfolio, not a near-term trading catalyst.

Price Chart

Loading chart...

Executive Summary

Cliramitug is a first-in-class antibody being developed by AstraZeneca (via its Alexion unit) to clear amyloid deposits from the heart in ATTR cardiomyopathy, a progressive and fatal disease. Phase 1/2 data showed a favorable safety profile and evidence of amyloid clearance. A large Phase 3 trial (DepleTTR-CM) is fully enrolled with results expected around late 2027 or 2028. Royalty Pharma (RPRX) is not the drug's developer; in July 2026 it acquired a 3-4% royalty interest in cliramitug from Neurimmune for up to $425 million. For RPRX, cliramitug is a long-term portfolio contributor with no near-term binary catalyst, and the royalty is a small slice of a diversified book of biopharma royalties.

How It Works

Cliramitug is an intravenous antibody therapy designed to clear toxic protein clumps (amyloid deposits) from the heart. In ATTR cardiomyopathy, the protein transthyretin misfolds and builds up in the heart muscle, stiffening it and leading to heart failure. Cliramitug works by binding to these misfolded deposits and flagging them for removal by the immune system, potentially reversing the damage rather than just slowing new buildup.

Trial Status

The pivotal Phase 3 DepleTTR-CM trial (NCT06183931) is active but no longer recruiting, having enrolled more than 1,100 adults with ATTR-CM across 212 sites in ~28 countries. Patients receive monthly intravenous infusions of cliramitug or placebo for at least two years and up to four years. The primary endpoint is a composite of all-cause mortality and cardiovascular clinical events. Phase 1 results published in NEJM (2023) showed no drug-related serious adverse events and dose-dependent reductions in cardiac amyloid burden. Long-term open-label extension data published in Nature Medicine (2026) showed sustained safety and further amyloid depletion.

The Two-Sided Case

▲ Bull Case4
Cliramitug targets a novel mechanism (amyloid depletion) that could differentiate it from existing stabilizers like Pfizer's tafamidis and BridgeBio's Attruby, which only prevent new amyloid formation.
Phase 1/2 data published in NEJM and Nature Medicine showed no drug-related serious adverse events and dose-dependent reductions in cardiac amyloid burden, supporting the therapeutic hypothesis.
AstraZeneca has guided peak sales potential of $3-5 billion for cliramitug, and the ATTR-CM market is projected to grow rapidly (estimates range from $17B in 2026 to $45B+ by 2030).
Royalty Pharma paid only $125M upfront (of up to $425M total) for a 3-4% royalty, limiting downside if the drug fails while offering leveraged upside if it succeeds.
▼ Bear Case4
The Phase 3 DepleTTR-CM trial is event-driven (mortality and cardiovascular events) and may take years to read out; primary completion is not expected until at least December 2027.
Pfizer's tafamidis franchise generated ~$6.3B in 2025 and is deeply entrenched, with patent protection extended to 2031 via settlements. BridgeBio's Attruby and Alnylam's therapy are also competing in the space.
Royalty Pharma's 3-4% royalty is a thin slice of any future sales. Even at $3-5B in peak sales, the annual royalty would be $90-200M, modest relative to RPRX's ~$3.5B annual portfolio receipts.
The $175M in contingent milestone payments means Royalty Pharma's total outlay could rise to $425M before the drug generates any royalty revenue, and clinical or regulatory setbacks could leave those milestones unpaid.

Upcoming Catalysts

  • Phase 3 DepleTTR-CM topline readout (primary completion estimated December 2027)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Royalty Pharma plc PRESS-RELEASE RPRX ·Originating report

Sources · 10

Hover a chip for the title
1 neurimmune.com2 royaltypharma.com3 nature.com4 clinicaltrials.gov5 adisinsight.springer.com6 nejm.org7 fiercebiotech.com8 biospace.com9 amyloidosisnewstoday.com10 royaltypharma.com